A Phase 3 interventional study of Medical Standard of Care for ITP and Romiplostim in Idiopathic Thrombocytopenic Purpura, Thrombocytopenia and Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-08.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 6 under way, 2 of them phase 3. romiplostim · Purpura, Thrombocytopenic, Idiopathic.
Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, this one is the 4th largest by enrollment, is one of 2 that started in 2006, is one of 13 in phase 3, and was the 7th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →5 of the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–100
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 14+
Wuhan Union Hospital, China · Sites in China
Ages 18–75
Nahda University · Sites in Egypt
Ages 18–65
By country, each count listing its studies:
romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 13 · Phase 4 3
First in 2002; this study’s year is marked. 2 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 234 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 62 across the 29 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 29 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
18 studies in Purpura, Thrombocytopenic, Idiopathic by Amgen: 1 open now, 1 under way, 1 of them phase 3. Of 17 finished, 13 (76%) have results posted.
Among the 18 studies in Purpura, Thrombocytopenic, Idiopathic by Amgen, this one is the 3rd largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2006, is one of 10 in phase 3, and was the 6th registered.
Amgen’s Purpura, Thrombocytopenic, Idiopathic studies by the year they started, since 2002.
2 of the studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07206823The First Affiliated Hospital of Soochow UniversityEfficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia | 2027-02-28 |
| NCT07612319The First Affiliated Hospital of Soochow UniversityRomiplostim for Oral TPO-RA Resistant ITP | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 18 in Purpura, Thrombocytopenic, Idiopathic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase 3b, multi-center, randomized, Standard of Care (SOC)-controlled, open-label, 52-week treatment study to compare romiplostim to medical SOC for Idiopathic Thrombocytopenia Purpura (ITP), with a 6-month Safety Follow-up. Patients randomized to romiplostim must complete the taper or discontinuation of medical SOC for ITP as soon as medically feasible after the initiation of romiplostim. After the completion or discontinuation of the study treatment period, any participant who does not transfer in to another romiplostim study will complete a 6-month Safety Follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Romiplostim administered by subcutaneous injection once weekly at a starting dose of 3 μg/kg, adjusted to a maximum dose of 10 μg/kg to maintain a platelet count between 50 and 200 x 10\^9/L for up to 52 weeks.
Biological: Romiplostim
Medical standard of care treatments were selected and prescribed by the investigator according to standard institutional practices or therapeutic guidelines and administered for up to 52 weeks.
Drug: Medical Standard of Care for ITP
Also known as: AMG 531
Number of Participants With Splenectomy During 52-Week Treatment Period
Occurrence of a splenectomy. Participants who discontinued study during the treatment period prior to reporting a splenectomy were considered as having had a splenectomy.
Time frame: 52 weeks
Number of Participants With Treatment Failure During 52-Week Treatment Period
Treatment failure was defined by platelet counts ≤ 20 x 10\^9/L for 4 consecutive weeks at the highest recommended dose and schedule, a major bleeding event, or change in therapy due to an intolerable side effect or bleeding symptom.
Time frame: 52 weeks
Time to Splenectomy
Time to splenectomy in days calculated from date of randomization to date of splenectomy, or censored at date of end of treatment visit if no splenectomy was done during treatment period.
Time frame: 52 weeks
Percentage of Participants With Platelet Response
Platelet response was defined as platelet counts \> 50 x 10\^9/L, measured at each study visit (excluding those within 8 weeks of prior rescue medication use) up to the time of splenectomy or the end of initial treatment period, whichever occurred first.
Time frame: Weeks 1-8, and Weeks 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52
Change in ITP-PAQ Physical Health Domain of Symptoms
Change from Baseline in the Immune Thrombocytopenic Purpura (ITP) Patient Assessment Questionnaire (PAQ) physical health domain of symptoms. This domain has a range of 0 to 100, with higher scores indicating a better health-related quality of life. Model included fixed effects of baseline assessment, geographic region, treatment group, assessment week, splenectomy status and treatment group-by-assessment week interaction. Treatment group and splenectomy status are time-varying covariates.
Time frame: Baseline and 52 weeks
Change in ITP-PAQ Physical Health Domain of Fatigue
Change from Baseline in the Immune Thrombocytopenic Purpura (ITP) Patient Assessment Questionnaire (PAQ) physical health domain of fatigue. This domain has a range of 0 to 100, with higher scores indicating a better health-related quality of life. Model included fixed effects of baseline assessment, geographic region, treatment group, assessment week, splenectomy status and treatment group-by-assessment week interaction. Treatment group and splenectomy status are time-varying covariates.
Time frame: Baseline and 52 weeks
Change in ITP-PAQ Physical Health Domain of Bother
Change from Baseline in the Immune Thrombocytopenic Purpura (ITP) Patient Assessment Questionnaire (PAQ) physical health domain of bother. This domain has a range of 0 to 100, with higher scores indicating a better health-related quality of life. Model included fixed effects of baseline assessment, geographic region, treatment group, assessment week, splenectomy status and treatment group-by-assessment week interaction. Treatment group and splenectomy status are time-varying covariates.
Time frame: Baseline and 52 weeks
Change in ITP-PAQ Physical Health Domain of Activity
Change from Baseline in the Immune Thrombocytopenic Purpura (ITP) Patient Assessment Questionnaire (PAQ) physical health domain of activity. This domain has a range of 0 to 100, with higher scores indicating a better health-related quality of life. Model included fixed effects of baseline assessment, geographic region, treatment group, assessment week, splenectomy status and treatment group-by-assessment week interaction. Treatment group and splenectomy status are time-varying covariates.
Time frame: Baseline and 52 weeks
First Subject Enrolled: 20-Dec-2006 Last Subject Enrolled: 01-Nov-2007
| Milestone | Standard of Care | Romiplostim |
|---|---|---|
| Started | 77 | 157 |
| Received treatment | 75 | 154 |
| Switched to romiplostim group | 2 | 0 |
| Completed | 60 | 142 |
| Not completed | 17 | 15 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Death | 2 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 6 | 6 |
| Withdrew: Other | 2 | 2 |
| Withdrew: Ineligibility determined | 1 | 1 |
| Withdrew: Noncompliance | 1 | 1 |
| Withdrew: Requirement for alternative therapy | 1 | 0 |
| Milestone | Standard of Care | Romiplostim |
|---|---|---|
| Started | 43 | 30 |
| Completed | 34 | 18 |
| Not completed | 9 | 12 |
| Withdrew: Adverse event | 1 | 3 |
| Withdrew: Death | 3 | 0 |
| Withdrew: Withdrawal by subject | 2 | 3 |
| Withdrew: Other | 1 | 4 |
| Withdrew: Ineligibility determined | 1 | 1 |
| Withdrew: Noncompliance | 1 | 0 |
| Withdrew: Requirement for alternative therapy | 0 | 1 |
Occurrence of a splenectomy. Participants who discontinued study during the treatment period prior to reporting a splenectomy were considered as having had a splenectomy.
| Participants | Standard of Care | Romiplostim |
|---|---|---|
| Had splenectomy | 28 | 14 |
| Did not have splenectomy | 49 | 143 |
Treatment failure was defined by platelet counts ≤ 20 x 10\^9/L for 4 consecutive weeks at the highest recommended dose and schedule, a major bleeding event, or change in therapy due to an intolerable side effect or bleeding symptom.
| Participants | Standard of Care | Romiplostim |
|---|---|---|
| Had treatment failure | 23 | 18 |
| Did not have treatment failure | 54 | 139 |
Time to splenectomy in days calculated from date of randomization to date of splenectomy, or censored at date of end of treatment visit if no splenectomy was done during treatment period.
| days | Standard of Care | Romiplostim |
|---|---|---|
| Time to Splenectomy | NA (NA to NA) | NA (NA to NA) |
Platelet response was defined as platelet counts \> 50 x 10\^9/L, measured at each study visit (excluding those within 8 weeks of prior rescue medication use) up to the time of splenectomy or the end of initial treatment period, whichever occurred first.
| percentage of participants | Standard of Care | Romiplostim |
|---|---|---|
| Week 1 [N=75, 154] | 6.7 | 3.9 |
| Week 2 [N=71, 153] | 28.2 | 75.8 |
| Week 3 [N=70, 152] | 34.3 | 73.0 |
| Week 4 [N=170, 152] | 30.0 | 73.7 |
| Week 5 [N=68, 152] | 32.4 | 71.1 |
| Week 6 [N=66, 151] | 30.3 | 74.2 |
| Week 7 [N=66, 151] | 30.3 | 75.5 |
| Week 8 [N=65, 151] | 29.2 | 68.2 |
| Week 12 [N=62, 149] | 25.8 | 79.2 |
| Week 16 [N=61, 147] | 34.4 | 82.3 |
| Week 20 [N=58, 139] | 36.2 | 83.5 |
| Week 24 [N=58, 138] | 31.0 | 92.0 |
| Week 28 [N=57, 137] | 40.4 | 88.3 |
| Week 32 [N=55, 135] | 34.5 | 87.4 |
| Week 36 [N=54, 135] | 33.3 | 89.6 |
| Week 40 [N=52, 134] | 38.5 | 88.8 |
| Week 44 [N=51, 131] | 51.0 | 86.3 |
| Week 48 [N=48, 130] | 41.7 | 88.5 |
| Week 52 [N=38, 122] | 50.0 | 90.2 |
Change from Baseline in the Immune Thrombocytopenic Purpura (ITP) Patient Assessment Questionnaire (PAQ) physical health domain of symptoms. This domain has a range of 0 to 100, with higher scores indicating a better health-related quality of life. Model included fixed effects of baseline assessment, geographic region, treatment group, assessment week, splenectomy status and treatment group-by-assessment week interaction. Treatment group and splenectomy status are time-varying covariates.
| Units on a scale | Standard of Care | Romiplostim |
|---|---|---|
| Change in ITP-PAQ Physical Health Domain of Symptoms | 12.5 ± 2.1 | 16.0 ± 1.9 |
Change from Baseline in the Immune Thrombocytopenic Purpura (ITP) Patient Assessment Questionnaire (PAQ) physical health domain of fatigue. This domain has a range of 0 to 100, with higher scores indicating a better health-related quality of life. Model included fixed effects of baseline assessment, geographic region, treatment group, assessment week, splenectomy status and treatment group-by-assessment week interaction. Treatment group and splenectomy status are time-varying covariates.
| Units on a scale | Standard of Care | Romiplostim |
|---|---|---|
| Change in ITP-PAQ Physical Health Domain of Fatigue | 9.5 ± 3.2 | 11.2 ± 3.1 |
Change from Baseline in the Immune Thrombocytopenic Purpura (ITP) Patient Assessment Questionnaire (PAQ) physical health domain of bother. This domain has a range of 0 to 100, with higher scores indicating a better health-related quality of life. Model included fixed effects of baseline assessment, geographic region, treatment group, assessment week, splenectomy status and treatment group-by-assessment week interaction. Treatment group and splenectomy status are time-varying covariates.
| Units on a scale | Standard of Care | Romiplostim |
|---|---|---|
| Change in ITP-PAQ Physical Health Domain of Bother | 13.0 ± 2.7 | 16.8 ± 2.5 |
Change from Baseline in the Immune Thrombocytopenic Purpura (ITP) Patient Assessment Questionnaire (PAQ) physical health domain of activity. This domain has a range of 0 to 100, with higher scores indicating a better health-related quality of life. Model included fixed effects of baseline assessment, geographic region, treatment group, assessment week, splenectomy status and treatment group-by-assessment week interaction. Treatment group and splenectomy status are time-varying covariates.
| Units on a scale | Standard of Care | Romiplostim |
|---|---|---|
| Change in ITP-PAQ Physical Health Domain of Activity | 8.2 ± 3.7 | 17.1 ± 3.5 |
Collected over 52 week treatment period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Standard of Care | — | 28/73 (38.4%) | 60/73 (82.2%) |
| AMG 531 | — | 36/156 (23.1%) | 136/156 (87.2%) |
| Event | Standard of Care | AMG 531 |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 8/73 | 6/156 |
| Idiopathic thrombocytopenic purpuraBlood and lymphatic system disorders | 3/73 | 0/156 |
| Abdominal painGastrointestinal disorders | 2/73 | 1/156 |
| PneumoniaInfections and infestations | 2/73 | 4/156 |
| Oedema peripheralGeneral disorders | 0/73 | 3/156 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/73 | 3/156 |
| CoagulopathyBlood and lymphatic system disorders | 1/73 | 0/156 |
| ArrhythmiaCardiac disorders | 1/73 | 0/156 |
| Atrial fibrillationCardiac disorders | 1/73 | 0/156 |
| Cardiac failure congestiveCardiac disorders | 1/73 | 0/156 |
| Event | Standard of Care | AMG 531 |
|---|---|---|
| HeadacheNervous system disorders | 14/73 | 54/156 |
| FatigueGeneral disorders | 16/73 | 43/156 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 17/73 | 29/156 |
| NasopharyngitisInfections and infestations | 14/73 | 36/156 |
| ContusionInjury, poisoning and procedural complications | 13/73 | 22/156 |
| PetechiaeSkin and subcutaneous tissue disorders | 13/73 | 25/156 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/73 | 25/156 |
| NauseaGastrointestinal disorders | 6/73 | 24/156 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/73 | 23/156 |
| DiarrhoeaGastrointestinal disorders | 4/73 | 21/156 |
| Age, Continuous(Years) | Standard of Care | Romiplostim | Total |
|---|---|---|---|
| Mean | 54.7 ± 19.3 | 54.8 ± 18.8 | 54.7 ± 18.9 |
| Sex: Female, Male(Participants) | Standard of Care | Romiplostim | Total |
|---|---|---|---|
| Female | 46 | 85 | 131 |
| Male | 31 | 72 | 103 |
| Race/Ethnicity, Customized(Participants) | Standard of Care | Romiplostim | Total |
|---|---|---|---|
| White or Caucasian | 69 | 137 | 206 |
| Black or African American | 0 | 6 | 6 |
| Hispanic or Latino | 5 | 9 | 14 |
| Asian (Chinese, Bangladeshi, Indian, Pakistani) | 1 | 5 | 6 |
| American Indian or Alaska Native | 1 | 0 | 1 |
| Other | 1 | 0 | 1 |
No study locations are listed for this record.
Ran from Dec 2006 to primary completion in Nov 2008, 23 months.
Results were first posted in Jul 2013, 4 years 8 months after primary completion.
Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 23 months is close to that.
Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romiplostim
Purpura, Thrombocytopenic, Idiopathic →